Since 1982, people with diabetes have been able to inject human insulin made by bacteria. Before that, insulin was purified from the pancreases of cattle and pigs, the approach developed at the University of Toronto in 1921–1922 by Frederick Banting, Charles Best, James Collip and John Macleod, and some patients reacted to the animal protein. Making insulin in bacteria was possible because the genetic code is nearly universal: give E. coli a human gene with the right control sequences, and it makes the human protein. Biotechnology is the use of living things and their molecules to make products or solve problems, and modern genetic technology rests on a small toolkit: enzymes that cut DNA at exact sequences, an enzyme that glues DNA, carriers that move DNA into cells, and methods to copy, sort and read DNA. The same tools raise real questions. Who can own a modified organism? Should GM foods carry labels? Who may see your genetic information? This topic covers the tools first, then the issues.
Cutting and pasting DNA
Restriction enzymes (restriction endonucleases) are bacterial enzymes that cut DNA at specific recognition sites, usually 4–8 base pairs long. In nature they defend bacteria by chopping up the DNA of invading viruses; the bacterium protects its own DNA by adding methyl groups to its own recognition sites. Most recognition sites are palindromes: the sequence reads the same 5'→3' on both strands. EcoRI (from E. coli) recognizes 5'-GAATTC-3' and cuts between the G and the A on each strand. Because the two cuts are offset, each piece is left with a short single-stranded overhang, 5'-AATT, called a sticky end. Sticky ends made by the same enzyme are complementary, so any two pieces cut with that enzyme can base-pair with each other. Other enzymes, such as SmaI (which cuts CCC|GGG), cut straight across both strands and leave blunt ends with no overhang; blunt ends can be joined, but less efficiently. DNA ligase then forms phosphodiester bonds to seal the sugar-phosphate backbones, permanently joining the pieces. In a random sequence, any particular 6-base site appears on average once every base pairs, so a six-base cutter such as EcoRI makes fragments a few thousand base pairs long.
To make recombinant DNA (DNA that combines sequences from different sources), the gene of interest and a vector are cut with the same restriction enzyme. A common vector is a plasmid, a small circular DNA molecule that bacteria copy independently of their chromosome. A cloning plasmid has an origin of replication, a site for the restriction enzyme, and a selectable marker such as a gene for resistance to the antibiotic ampicillin. The cut gene and cut plasmid are mixed so their sticky ends pair, and ligase seals them. Bacteria are then transformed: treated with calcium chloride and a brief heat shock (or an electric pulse) so that some take up plasmids. Only a small fraction succeed, so the bacteria are spread on agar containing ampicillin. Cells without a plasmid die, and only transformed cells grow into colonies. For human insulin, the gene used is a copy made from the insulin mRNA with the enzyme reverse transcriptase, called complementary DNA (cDNA). This matters because bacteria cannot splice out introns, and cDNA made from mature mRNA has none. The transformed bacteria are grown in large fermentation tanks, and the insulin is purified.
Separating, copying and reading DNA
Gel electrophoresis separates DNA fragments by size. Samples are loaded into wells at one end of a slab of agarose gel, which sits in a buffer between two electrodes. DNA is negatively charged because of its phosphate groups, so when the current is on, every fragment moves toward the positive electrode; the wells are placed at the negative end. The gel is a tangled mesh of fibres: short fragments slip through easily and travel farther, while long fragments are held back. Every DNA molecule has the same charge per unit length, so size is the only thing that decides how far a fragment moves. A DNA ladder, a mixture of fragments of known sizes, runs in one lane as a ruler. Afterward the gel is stained with a dye that glows under UV or blue light. Each visible band is millions of copies of fragments of one size.
The polymerase chain reaction (PCR), invented by Kary Mullis in 1983, copies a chosen stretch of DNA billions of times in a few hours. The tube holds the template DNA, two short DNA primers that flank the target sequence, all four nucleotides (dNTPs), and Taq polymerase, a heat-stable DNA polymerase from Thermus aquaticus, a bacterium from hot springs. A thermal cycler repeats three steps: denaturation at about 95 °C separates the strands; annealing at about 55–65 °C lets the primers pair with their target sequences; extension at about 72 °C lets Taq build new strands from the primers. Each cycle doubles the number of copies, so after cycles ; 30 cycles turn one molecule into about . Sanger sequencing (1977) reads the order of bases. A polymerase copies the template in the presence of a small amount of dideoxynucleotides (ddNTPs), which lack the 3'-OH needed to add the next nucleotide, so a strand stops wherever one is added. The result is a set of fragments ending at every position, each end tagged with a colour for its base; sorted by size, they spell out the sequence. DNA fingerprinting compares short tandem repeats (STRs), places where a 2–6 base sequence is repeated back to back a number of times that varies between people. PCR copies about 20 STR loci, and the combined pattern is so variable that the chance of two unrelated people matching is far below one in a billion. Canada's National DNA Data Bank, run by the RCMP since 2000, stores STR profiles, and DNA evidence helped overturn the wrongful convictions of Guy Paul Morin (1995) and David Milgaard (1997).
Applications
| Application | How it works | Example |
|---|---|---|
| Reproductive cloning (somatic cell nuclear transfer) | The nucleus of a body cell is transferred into an egg whose own nucleus has been removed. An electric pulse starts division, and the embryo is implanted in a surrogate mother. The offspring is a genetic copy of the nucleus donor (except for mitochondrial DNA, which comes from the egg). | Dolly the sheep, born in 1996 at the Roslin Institute in Scotland, cloned from an adult mammary gland cell. It took 277 attempts. |
| Transgenic crops | A gene from another species is inserted to give the plant a new trait. | Bt corn carries a gene from the bacterium Bacillus thuringiensis for a protein toxic to certain insect larvae such as the European corn borer. Canola was bred in Canada in the 1970s; herbicide-tolerant GM canola now makes up about 95% of Canada's canola crop. |
| Transgenic animals | A gene is added to a fertilized egg so every cell of the animal carries it. | AquAdvantage salmon: Atlantic salmon with a growth-hormone gene from Chinook salmon, switched on by a promoter from the ocean pout, so it grows year-round and reaches market size faster. Health Canada approved it as food in 2016, the first GM animal approved for food in Canada. |
| Gene therapy | A working copy of a gene is delivered into a patient's cells, usually by a modified virus, to treat a disease caused by a faulty gene. Somatic gene therapy affects only the patient; germ-line changes would be inherited. | Approved treatments exist for an inherited form of blindness and for spinal muscular atrophy. |
| CRISPR-Cas9 gene editing | A guide RNA matching the target sequence leads the Cas9 enzyme to that spot, where it cuts both strands. The cell's repair then disables the gene or inserts a supplied sequence. | Adapted from a bacterial immune system by Jennifer Doudna and Emmanuelle Charpentier (Nobel Prize in Chemistry, 2020). The first approved CRISPR therapy, for sickle-cell disease, arrived in 2023. |
| Human Genome Project | An international effort (1990–2003) to sequence the roughly 3 billion base pairs of the human genome. | Found only about 20 000 protein-coding genes; a fully complete (telomere-to-telomere) sequence followed in 2022. Cheap sequencing now supports personalized medicine. |
Issues: law, regulation and ethics
| Case, law or agency | What it decided or does |
|---|---|
| Harvard College v. Canada (Supreme Court of Canada, 2002) | Harvard sought a patent on the oncomouse, a mouse modified to be prone to cancer for research. The Court ruled 5–4 that higher life forms such as plants and animals are not patentable "inventions" under the Patent Act, although the process used to make the mouse could be patented. The United States and Europe had granted patents on the mouse. |
| Monsanto Canada v. Schmeiser (Supreme Court of Canada, 2004) | Saskatchewan farmer Percy Schmeiser saved and planted canola seed containing Monsanto's patented herbicide-tolerance gene without a licence. The Court ruled 5–4 that the patent on the modified gene and cells was valid and that growing the plants was "use" of the invention, so he had infringed it. He did not have to pay damages, because he had not profited from the trait (he had not sprayed the herbicide). |
| Health Canada | Assesses the safety of novel foods, including GM foods, before they can be sold (for example, checking for new allergens or changed nutrition). |
| Canadian Food Inspection Agency (CFIA) | Regulates "plants with novel traits", including the environmental release of GM crops, and livestock feeds. |
| Environment and Climate Change Canada | With Health Canada, assesses the environmental and health risks of new living organisms, such as GM fish or microbes, under the Canadian Environmental Protection Act (CEPA). |
| Assisted Human Reproduction Act (2004) | Makes it a crime to create a human clone for any purpose, which includes reproductive cloning, and to alter the human genome in a way that could be passed to descendants. |
| Genetic Non-Discrimination Act (2017) | Makes it illegal to require a person to take a genetic test, or reveal test results, as a condition of providing goods, services or a contract such as insurance; adds genetic characteristics to the Canadian Human Rights Act. The Supreme Court of Canada upheld it in 2020. |
- Regulates by product: any plant with a novel trait is assessed, whether it came from genetic engineering, chemical mutagenesis or conventional breeding
- GM food labelling is voluntary (a national standard sets the rules); labels are mandatory only for health or safety changes such as a new allergen or altered nutrition
- Many GM crops approved and widely grown (canola, corn, soybeans, sugar beets)
- Higher life forms cannot be patented (Harvard mouse), but modified genes and cells can (Schmeiser)
- Regulates by process: organisms made by genetic engineering go through a separate, stricter approval system
- Mandatory labelling of foods containing more than 0.9% GM material
- Very few GM crops grown commercially; member states may ban cultivation on their territory
- Transgenic animals such as the oncomouse can be patented if an ethics test finds the benefit outweighs animal suffering
| Issue | Arguments in favour | Concerns raised |
|---|---|---|
| GM crops and food | Higher yields, less insecticide spraying (Bt crops), crops that tolerate drought or disease, better nutrition (Golden Rice with provitamin A). Approved GM foods pass safety assessment. | Herbicide-resistant weeds and insect resistance from heavy use; genes spreading to wild relatives or organic farms; seed supply controlled by a few companies; consumers' right to know what they eat. |
| Patenting life forms | Patents reward expensive research, encourage investment, and require inventors to publish their methods. | Living things are not human inventions; farmers' traditional practice of saving seed; patents can limit research access. |
| Cloning and gene editing | Research into disease, conserving endangered species, therapies that could cure inherited disorders. | Low success rates and animal welfare in cloning; safety of changes that could be inherited; future generations cannot consent; fears of "designer babies". |
| Genetic information | Personalized medicine, early diagnosis, forensic identification, reuniting families. | Discrimination by insurers or employers; privacy of relatives who share your DNA; security and consent for DNA databases. |